U.S. Markets closed

Vitality Biopharma, Inc. (VBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3900+0.0400 (+11.43%)
At close: 3:58PM EDT

Vitality Biopharma, Inc.

1901 Avenue of the Stars
2nd Floor
Los Angeles, CA 90067
United States
530 231 7800

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Hon. Edward Farrell FeighanExec. Chairman136kN/A1948
Mr. Michael R. Cavanaugh CPA, J.D.CEO & Director256kN/AN/A
Dr. Brandon Joel Zipp Ph.D.Scientific Co-Founder & Chief Science Officer195kN/A1981
Mr. Richard McKilligan J.D., M.B.A.CFO, Counsel & Sec.185kN/A1964
Dr. J. Jeremiah MannVP of Operations & Sr. AgronomistN/AN/AN/A
Dr. Dong YuejinPartnerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vitality Biopharma, Inc. focuses on developing cannabinoid pharmaceutical prodrugs in the United States. The company produces approximately 25 novel cannabosides, including glycosylated tetrahydrocannabinol (THC), cannabidiol, cannabidivarin, and cannabinol. It is developing THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was incorporated in 2007 and is headquartered in Los Angeles, California.

Corporate Governance

Vitality Biopharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.